Druggable Targets in Diseases Due to Mucociliary Dysfunction and Bronchiectasis

Chiesi Farmaceutici S.p.A, one of the top 50 pharmaceutical companies in the world, is seeking novel targets/therapeutics for respiratory diseases with a clinical unmet need, such as chronic obstructive pulmonary disorder (COPD), non–CF bronchiectasis and mucociliary dysfunction, that have a competitive edge on current treatments.

Approaches of Interest:

• Novel druggable targets and therapeutic approaches for respiratory diseases including COPD, non-CF bronchiectasis, mucociliary dysfunction, primary ciliary dyskinesia etc.
• Open to different modalities, ...